Purpose: To report the use of direct oral anticoagulants (DOACs) for stroke prevention in patients with atrial fibrillation in Scotland and advocate the standardisation of drug utilisation research methods. (apixaban) to 60.6% (dabigatran) and 12 months persistence from 60.1% (dabigatran) to 85.5% (apixaban). Adherence to treatment with all DOACs was good: Overall DOAC median medication refill adherence was 102.9% (interquartile range 88.9%-115.5%), and 82.3% of patients had a medication refill adherence > 80%.
instructions. 1 Nonadherence to drugs is widespread [1] [2] [3] and has been linked to increases in morbidity, premature death, and health care expenditure; 1, 4, 5 especially nonadherence to drugs with complex pharmacological profiles such as warfarin and other vitamin K antagonists (VKAs) is known to negatively affect treatment outcomes. [6] [7] [8] [9] Warfarin is used for multiple cardiovascular conditions, and high discontinuation rates of warfarin treatment have been reported in clinical trials and observational studies; [10] [11] [12] poor adherence has been ascribed to a variety of issues, from the occurrence of bleeding events to the inconvenience of treatment. 6, [13] [14] [15] As warfarin is widely used long-term in patients with atrial fibrillation (AF)-a common condition causing irregular heartbeat and, as such, a major independent risk factor for stroke 16, 17 -efforts to replace warfarin have resulted in 4 new direct oral anticoagulants (DOACs) being introduced since 2008: dabigatran, a direct thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, direct factor Xa inhibitors.
Treatment with DOACs follows easier dosing schemes and theoretically requires no monitoring, primarily because their therapeutic windows are wider and interactions with other drugs/foods are shown to be less than with warfarin. 18, 19 Treatment with DOACs is deemed as effective and safe as with warfarin; [20] [21] [22] [23] the effect of nonadherence on bleeding risk and stroke incidence among AF patients has been addressed but as yet not intensely studied. 24, 25 Recently, concerns have been raised about the potential impact of no monitoring and the presence of multimorbidity and polypharmacy on DOAC adherence. 24, [26] [27] [28] [29] Knowledge about patients' adherence to DOACs in real life is however still limited, and studies conducted thus far differ in scale, methodology, and focus. 25, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Results emerging from DUR studies are frequently used to compare uptake and use of drugs over time and between regions. Additionally, information on treatment adherence can be used to improve the accuracy of drug exposure estimates when investigating treatment outcomes in clinical practice-as compared to clinical trials results. 42 Nevertheless, although a comprehensive framework of drug adherence and a common terminology for measuring adherence have been proposed by the European Society for Patient Adherence, Compliance and Persistence, 43 DUR studies still make use of a variety of definitions and measurements, with methods of calculation also differing. [44] [45] [46] The objective of this study is therefore 2-fold: first, to report on the use of DOACs for stroke prevention in patients with AF identified in Scottish secondary care; and second, to advocate the standardisation of DUR by applying an evolving methods approach, based on a sound theoretical framework and well-documented measurements of adherence.
| METHODS
In Scotland (population approximating 5.3 million   47 ), all residents are covered by the publicly funded National Health Service (NHS), with most clinical services including prescriptions provided free of charge at the point of care. 48 Prescription details have been derived from the Prescribing Information System (PIS)-an NHS Scotland national database created primarily for reimbursement purposes. 49 The PIS holds data on the prescribed and dispensed items, patients, and prescribers, including a range of drug-specific information based on the British National Formulary. 49 • Adherence to DOAC treatment was good, and switching from DOAC to warfarin was low. However, discontinuation and persistence rates were variable.
• Standardisation of drug utilisation studies using the ESPACOM framework, combining measurements of discontinuation, persistence, and adherence, is strongly advocated. 56 As no "gold standard" to quantify adherence has been agreed upon, triangulation of measurements selected based on a literature review has been applied. See Table 1 for details. Drug utilisation measures are rations and are summarised using medians and interquartile ranges (IQRs).
Kaplan-Meier survival analysis has been used to calculate median time to discontinuation; follow-up has been censored after 1 year for apixaban and after 2 years for dabigatran and rivaroxaban. Events have been coded as 1 = treatment discontinuation and 0 = still on treatment at end of follow-up. All data analyses have been conducted using the R software, version 3.3.1.
57
Because of the nature of the study, ethical approval was not required; however, use of the data has been approved by the appropriate Privacy Advisory Committee. The data were hosted and managed by the NHS Scotland National Safe Haven.
| RESULTS
A total of 5398 patients were included in the study, 48.1% of whom with DOACs were prescribed to 5.0% and 2.2% of patients, respectively. looking at 6 months intervals rather than assessing patients' entire treatment periods; see Table 3 for details. 32, 35 Nevertheless, two important differences need to be highlighted: First, adherence to treatment was considerably higher in our study than has been reported in other studies conducted on a national level; 25, 33 and second, switches from DOACs to VKAs were much less common than in previous observational studies. 31, 36, 38 The crude discontinuation rate and 12 months persistence to DOAC treatment in Scotland were 35.6% and 75.9%, respectively, and similar rates have been reported before; 35, 41 however, most studies reporting on discontinuation and/or persistence either did not explicitly describe how rates have been calculated or did not clearly distinguish between the different concepts of discontinuation and persistence. In our study, 48.3% of patients discontinuing treatment subsequently received at least one additional prescription for any DOAC, ie, eventually resumed treatment. When allowing for treatment interruptions by using only the number of patients where no subsequent DOAC prescriptions were recorded-a figure considerably influenced by length of follow-up, as more patients might reinitiate treatment over time-the crude DOAC discontinuation rate was 22.0%, highlighting that the method of calculation where patients are censored after the occurrence of a first discontinuation event likely leads to an overestimation of discontinuation. This lower discontinuation rate is also more in agreement with the persistence rates found in this study, calculated using the anniversary method that is insensitive to periods of treatment interruptions. 56 The percentage of patients switching from a DOAC to VKA treatment was low in this study (11.0%) compared to patients in Denmark (51.2%) and Japan (54%), but higher than in England (6.0%), and similar to the 1-year follow-up EORP-AF pilot registry (11.8%); 35, 36, 38, 59 the reasons for these diverse findings are unclear, but might be rooted either in differences in clinical guidelines and physicians' preferences, or in timing of studies and availability of DOACs.
Although many studies report on DOACs as a group rather than separately by individual drugs, our results confirm previous findings indicating sizable differences between individual drugs: Dabigatran frequently exhibits discontinuation rates higher than rivaroxaban and apixaban. 32, 38 Consequently, 12 months persistence has reportedly (rivaroxaban), and 85.5% (apixaban).
Discontinuation of DOAC treatment has often been attributed to changes in underlying disease severity, including restoration of sinus rhythm, worsening kidney function, and side effects including bleeding events or, particularly in case of dabigatran, gastrointestinal disturbances. 31, 38, 41 Because of the data available for this study, specific reasons for treatment discontinuations among the study population remain unknown.
Adherence to medication was high for all drugs and did not considerably decline over time. Treatment gaps were rare, patients generally having enough medication to cover the treatment period; median medication refill adherence, and compliance rate during the first 6 months of treatment, indicated oversupply rather than undersupply of drugs, although these findings might be due to the timing of prescriptions.
High median adherence to DOAC treatment has been shown before:
between 94% and 99.7% 37, 39 for dabigatran and up to 100% for rivaroxaban and apixaban. 30 Results differ however, which might in part be due to distinct methodology, as calculation methods for adherence This study has a number of limitations. First, by identifying eligible patients to be included in the study in secondary care, patients diagnosed and treated exclusively in primary care were not captured. A recent study, conducted in England, identified that 42.1% of AF patients had an initial diagnosis in primary care; 60 however, as many of these patients are relatively elderly, a proportion might subsequently be admitted to hospital, and therefore, the percentage of patients potentially not included in our study is likely to be lower than 40%. We do not anticipate this having a large impact on our findings regarding adherence, persistence, and discontinuation. Second, the data used for analysis have not been collected for the specific purpose of this study but were gathered routinely in daily care. Therefore, not all desirable information was present; in particular, no indication for why drugs have been prescribed has been available. This might have resulted in the inclusion of patients who had AF but were treated with DOACs for other reasons-specifically, treatment with any DOAC for up to 6 months due to deep vein thrombosis-potentially leading to imprecision in results due to diverging anticipated treatment lengths and dosing schedules. In Figure 2 , there is a small drop at 180 days of only about 3%, so the impact of this on persistence is likely to be small. Dose instructions as recorded by the prescriber have been used supplementary to drug supply based on standard dosing guidelines to To calculate adherence, only patients who received at least 2 prescriptions have been included. Discrepancies between the total number of patients receiving 2 prescriptions for any DOAC (n = 4555) and the sum of patients receiving at least 2 prescriptions for dabigatran, rivaroxaban, or apixaban (n = 4507) are due to patients switching drugs after only one prescription for an initial drug.
a Includes all patients with at least 2 prescriptions during the study period.
b Includes only patients with sufficient follow-up time to cover the respective prescription period.
limit the impact of variations in dosing schedules on adherence. Finally, as prescription records do not cover secondary care, in-patient periods are not included; this might have impacted adherence and persistence, as hospital days could have appeared to be treatment interruptions.
Sensitivity analysis of the lengths of admissible gaps and the additional measurement of treatment cessation have been used to account for the potential effect of in-patient episodes on discontinuation and persistence.
This study has nevertheless several strengths: Access to health care is universal, and electronic health records in Scotland cover the entire population. Because of the presence of a unique patient identifier, records can easily and reliably be linked; a large variety of variables is therefore available, including those essential for calculating adherence to medication. Furthermore, PIS and SMR01 have previously been used for research, and validity and accuracy of the data has been established. 49, 52 5 | CONCLUSION
In Scotland, adherence to DOAC treatment was high, and switching from DOAC to warfarin was low. However, discontinuation and persistence rates were variable-although treatment interruptions were often temporary. The effects of nonadherence, including treatment interruptions, on the safety and effectiveness of DOACs need to be investigated further; more research is needed to analyse whether treatment with DOACs does indeed result in better disease outcomes as compared to warfarin.
To decrease the inconsistencies in drug utilisation methodology impacting the comparability of results across studies, the use of a coherent framework-using a combination of discontinuation, persistence, and adherence-and the standardisation of measurements is strongly advocated.
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